Testing Experimental Treatment of Rheumatoid Arthritis

Eligibility Details: Key inclusion criteria: - ≥18 years of age - Has had RA for ≥6 months and was not diagnosed before 16 years of age - Has active disease, as defined by having both:* - ≥6/68 tender/painful joints (tender joint count [TJC]), and - ≥6/66 swollen joints (swollen joint count [SJC]) - Has had an inadequate response despite currently taking at least one and at the most two concomitant csDMARDs for at least 12 weeks, from the following: - Methotrexate (MTX) - Hydroxychloroquine or chloroquine - Sulfasalazine - Leflunomide - Bucillamine - Iguratimod - Tacrolimus - Has had inadequate response to at least one bDMARD at an approved dose and/or at least one JAK inhibitors at an approved dose. In both cases this may be with or without combination with a csDMARD. - If surgical treatment of a joint has been performed, that joint cannot be counted in the TJC or SJC. Key exclusion criteria: - Has had any active and/or recurrent infections (excluding recurrent fungal infections of the nail bed) or has required management of acute or chronic infections. - Has received prior treatment with an antagonist of GM-CSF or its receptor. - Has known infection with human immunodeficiency virus (HIV) or current acute or chronic hepatitis B and/or hepatitis C.